Becker’s asked C-suite executives from hospitals and health systems across the U.S. to share the biggest healthcare questions for 2025. The 34 executives featured in this article are all speaking at the Becker’s Healthcare 13th Annual CEO+CFO Roundtable on Nov. 3-6, 2025 at the Hilton Chicago. To learn more about this event, click here. If … Read more
Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that’s already generating more than $1 billion in quarterly sales, although it was approved only in late 2023. Zepbound’s prospects still look bright, but some recent developments point … Read more
DUBLIN–(BUSINESS WIRE)–The “Incretin-based Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034” report has been added to ResearchAndMarkets.com’s offering. The Incretin-based Drugs Market was valued at USD 37.4 billion in 2024, and is projected to reach USD 68.7 billion by 2034, rising at a CAGR of 6.3%. The market is categorized by drug … Read more
Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs WIRED Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro CNBC Lilly sues four compounders over copies of weight-loss drugs Reuters Eli Lilly sues Houston-based compounding pharmacy over alleged ‘knockoff’ obesity, diabetes drugs Houston Public Media Eli Lilly opens a new legal front in its battle … Read more
Big Pharma sues Houston compounding pharmacy over copycat weight loss drugs Houston Chronicle Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro CNBC Lilly sues four compounders over copies of weight-loss drugs Yahoo Finance Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs WIRED Eli Lilly opens a new legal front in its battle against … Read more
The anti-obesity drug market has the potential to be massive, with multiple analysts projecting it may reach at least $100 billion by 2030. As a result, many top healthcare companies are vying for a piece of the market, as doing so could generate significant revenue and profit growth. Pfizer (NYSE: PFE) has been one of … Read more
Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical data. The latest results show a high starting dose, fast titration model provides the same weight loss and worse tolerability than more measured approaches.
Rationale: Alcohol use disorder (AUD) remains a major public health challenge, yet effective pharmacotherapies are limited. As such, there is growing interest in repurposing medications with novel mechanisms of action. Glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for type 2 diabetes, have emerged as promising candidates due to effects on intake regulation and reward processing. … Read more
Injectable drugs like Ozempic and Mounjaro have become household names in the fight against obesity and type 2 diabetes. But for all their popularity, needles aren’t everyone’s favorite. Now, a new contender is stepping into the spotlight. It’s called Orforglipron, and it’s a daily weight loss pill that could be a game-changer in how we … Read more
